top of page
NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA...
Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in China
Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in China Initial launch of Generation 1.0...
NeuroSigma Announces Promotion of Dr. Colin Kealey to President
LOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) - NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion...
Press
bottom of page